Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 2
1992 1
1993 2
1994 2
1995 1
1996 3
1997 8
1998 3
1999 6
2000 23
2001 67
2002 58
2003 77
2004 120
2005 124
2006 181
2007 238
2008 338
2009 390
2010 502
2011 561
2012 659
2013 812
2014 888
2015 951
2016 966
2017 1020
2018 1103
2019 1165
2020 1410
2021 1565
2022 1548
2023 1574
2024 1311

Text availability

Article attribute

Article type

Publication date

Search Results

15,624 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant treatment for HER2-positive breast cancer.
Takada M, Toi M. Takada M, et al. Chin Clin Oncol. 2020 Jun;9(3):32. doi: 10.21037/cco-20-123. Epub 2020 Jun 3. Chin Clin Oncol. 2020. PMID: 32527117 Free article. Review.
The addition of trastuzumab to neoadjuvant chemotherapy roughly doubles the proportion of patients with HER2-positive breast cancer who achieve pathological complete response (pCR). Patients with pCR show better prognosis compared with those with resid …
The addition of trastuzumab to neoadjuvant chemotherapy roughly doubles the proportion of patients with HER2-positive breas …
Breast Cancer Treatment: A Review.
Waks AG, Winer EP. Waks AG, et al. JAMA. 2019 Jan 22;321(3):288-300. doi: 10.1001/jama.2018.19323. JAMA. 2019. PMID: 30667505 Review.
This review focuses on current approaches and evolving strategies for local and systemic therapy of breast cancer. OBSERVATIONS: Breast cancer is categorized into 3 major subtypes based on the presence or absence of molecular markers for estroge …
This review focuses on current approaches and evolving strategies for local and systemic therapy of breast cancer. OBSE …
Treatment of breast cancer.
Maughan KL, Lutterbie MA, Ham PS. Maughan KL, et al. Am Fam Physician. 2010 Jun 1;81(11):1339-46. Am Fam Physician. 2010. PMID: 20521754 Free article. Review.
Understanding breast cancer treatment options can help family physicians care for their patients during and after cancer treatment. ...In general, node-positive breast cancer is treated systemically with chemotherapy, endocr …
Understanding breast cancer treatment options can help family physicians care for their patients during and after ca …
Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.
Harbeck N. Harbeck N. Breast. 2022 Mar;62 Suppl 1(Suppl 1):S12-S16. doi: 10.1016/j.breast.2022.01.006. Epub 2022 Jan 19. Breast. 2022. PMID: 35148934 Free PMC article.
The availability of HER2-targeted therapy has dramatically improved patient outcome in HER2-positive (HER2+) early breast cancer (EBC) as recently demonstrated by the EBCTCTG metaanalysis on trastuzumab in HER2+ EBC: Adding …
The availability of HER2-targeted therapy has dramatically improved patient outcome in HER2-positive (HER2 …
Breast cancer.
Harbeck N, Gnant M. Harbeck N, et al. Lancet. 2017 Mar 18;389(10074):1134-1150. doi: 10.1016/S0140-6736(16)31891-8. Epub 2016 Nov 17. Lancet. 2017. PMID: 27865536 Review.
Primary conventional surgery is not the optimal choice for all patients any more. In triple-negative and HER2-positive early breast cancer, neoadjuvant therapy has become a commonly used option. Depending on clinical tumour subtype, therapeutic …
Primary conventional surgery is not the optimal choice for all patients any more. In triple-negative and HER2-positive early …
HER2-positive breast cancer.
Loibl S, Gianni L. Loibl S, et al. Lancet. 2017 Jun 17;389(10087):2415-2429. doi: 10.1016/S0140-6736(16)32417-5. Epub 2016 Dec 7. Lancet. 2017. PMID: 27939064 Review.
Anti-HER2 treatment for HER2-positive breast cancer has changed the natural biology of this disease. ...With survival rates of almost 5 years in women with metastatic HER2-positive breast cancer and 75% of pati …
Anti-HER2 treatment for HER2-positive breast cancer has changed the natural biology of this diseas …
HER2-positive advanced breast cancer treatment in 2020.
Cesca MG, Vian L, Cristóvão-Ferreira S, Pondé N, de Azambuja E. Cesca MG, et al. Cancer Treat Rev. 2020 Aug;88:102033. doi: 10.1016/j.ctrv.2020.102033. Epub 2020 May 22. Cancer Treat Rev. 2020. PMID: 32534233 Review.
HER2-positive breast cancer is an aggressive subtype identified in the 1980s. The development of therapies targeting the HER2 has improved outcomes. ...In 2019 the presentation of several trials evaluating new drugs and regimens in third-line ha …
HER2-positive breast cancer is an aggressive subtype identified in the 1980s. The development of therapies targe …
Biology and Treatment of HER2-Low Breast Cancer.
Nicolò E, Tarantino P, Curigliano G. Nicolò E, et al. Hematol Oncol Clin North Am. 2023 Feb;37(1):117-132. doi: 10.1016/j.hoc.2022.08.013. Hematol Oncol Clin North Am. 2023. PMID: 36435605 Review.
Current guidelines recommend a dichotomous classification of HER2 as either positive or negative, to guide clinicians in treatment decisions. Until now, only patients with HER2-positive breast cancer (BC) had been demonstrated to d …
Current guidelines recommend a dichotomous classification of HER2 as either positive or negative, to guide clinicians in tr …
Treatment of Breast Cancer in Young Adults.
Tesch ME, Partridge AH. Tesch ME, et al. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-12. doi: 10.1200/EDBK_360970. Am Soc Clin Oncol Educ Book. 2022. PMID: 35580291 Free article.
Although breast cancer is rare and understudied in adults age 40 and younger, recent epidemiologic data show an increasing incidence of breast cancer among young women in the United States and ongoing inferior long-term outcomes. ...Ovarian function su …
Although breast cancer is rare and understudied in adults age 40 and younger, recent epidemiologic data show an increasing inc …
Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?
Dempsey N, Sandoval A, Mahtani R. Dempsey N, et al. Curr Treat Options Oncol. 2023 Sep;24(9):1120-1137. doi: 10.1007/s11864-023-01108-w. Epub 2023 Jul 10. Curr Treat Options Oncol. 2023. PMID: 37428332 Review.
The current standard first-line therapy for patients with HER2+ metastatic breast cancer (MBC) is a taxane combined with trastuzumab and pertuzumab. ...Accordingly, it will be critical to identify biomarkers and mechanisms of resistance to optimize …
The current standard first-line therapy for patients with HER2+ metastatic breast cancer (MBC) is a taxane combi …
15,624 results
You have reached the last available page of results. Please see the User Guide for more information.